Aurobindo Pharma Limited's board has officially approved a significant share buyback proposal worth ₹800.00 crores at its meeting held on April 6, 2026. The pharmaceutical company will repurchase up to 54,23,728 fully paid-up equity shares at ₹1,475.00 per share, representing 0.93% of the total paid-up equity share capital.

Buyback Details and Structure

The board approved the buyback through the tender offer route, targeting all equity shareholders including promoters and promoter group members on a proportionate basis. The buyback will be conducted in accordance with SEBI (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013.

The buyback size represents 3.93% and 2.62% of the aggregate total paid-up equity share capital and free reserves as per standalone and consolidated financial statements respectively as at March 31, 2025. Transaction costs including brokerage, fees, taxes, and other expenses are excluded from the buyback size.

Governance and Timeline

The board has constituted a buyback committee with delegated powers to execute all necessary actions for the buyback process. Under SEBI regulations, the board retains flexibility to increase the buyback price and decrease the number of shares until one working day prior to the record date, provided the total buyback size remains unchanged.

Current Shareholding Pattern

As of December 31, 2025, the company's shareholding structure shows promoters and promoter group holding 51.82% with 30,09,48,721 shares. Mutual funds constitute the second-largest category at 19.52% with 11,33,67,285 shares, followed by foreign portfolio investors at 13.94%.

The company will release the public announcement and letter of offer detailing the complete process, timelines, and other requisite information in due course as per regulatory requirements.

Aurobindo Pharma Limited's board of directors has approved a significant restructuring move involving the transfer of its domestic branded generic pharmaceutical formulations products business to its wholly owned subsidiary. The decision was taken at a board meeting held on April 6, 2026, as part of the company's strategic initiative to streamline and accelerate domestic business operations.

Transaction Structure and Consideration

The transfer will be executed through a Business Transfer Agreement (BTA) on a slump sale basis, with the business being transferred as a going concern to Auropharm Limited (previously known as Auro Pharma Limited). The transaction details are structured as follows:

Financial Impact and Business Metrics

The domestic branded generic pharmaceutical formulations business represents a specific portion of Aurobindo Pharma's overall operations. The financial contribution of this business unit demonstrates its focused scope within the company's broader portfolio:

Strategic Rationale and Business Consolidation

The transaction aligns with the group's objective to consolidate domestic pharmaceutical operations under Auropharm Limited, which currently operates the non-oncology formulations business previously acquired from Khandelwal Laboratories Limited. This consolidation strategy aims to enhance operational efficiency and provide a more focused approach toward domestic pharmaceutical business growth.

The transfer encompasses comprehensive business assets including movable assets, employees, contracts, intellectual property, licenses, permits, consents, approvals, trade receivables, inventory, and trade payables. Auropharm Limited is engaged in the business of trade of branded generic formulations and pharmaceutical products in India.

Regulatory and Related Party Considerations

As Auropharm Limited is a wholly owned subsidiary of Aurobindo Pharma Limited, the transaction constitutes a related party transaction under SEBI regulations. However, provisions relating to related party transactions under Section 188 of the Companies Act, 2013 and Regulation 23(5)(b) of SEBI Listing Regulations are not applicable for transactions between a holding company and its wholly owned subsidiary.

The transaction is structured outside the Scheme of Arrangement, though Regulation 37A(1) of SEBI Listing Regulations does not apply as it involves a slump sale rather than the sale of the whole or substantially the whole undertaking. The accounts of Auropharm Limited will continue to be consolidated with the parent company, ensuring no impact on the consolidated financial statements.

Implementation Timeline

The completion of the business transfer is estimated within 90 to 120 days from the date of the Business Transfer Agreement, subject to satisfactory completion of customary conditions precedent. Once completed, the economic benefits of the transferred business will flow to Auropharm Limited effective April 1, 2026. The transaction will not result in any change to the shareholding pattern of Aurobindo Pharma Limited.